Resources
National Governance Framework for Cancer and Population Screening
The National Governance Framework for Cancer and Population Screening outlines the governance arrangements of our various committees and groups.
Invasive Group A Streptococcal (iGAS) Disease – CDNA National guidelines for Public Health Units
These guidelines outline Australia’s national minimum standard for surveillance, laboratory testing, case management and contact management for Invasive Group A Streptococcal (iGAS) disease.
National Site of Recognition Steering Committee communique – September 2023
Details of the sixth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.
Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.
Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 3 October 2023
This communique provides a summary of the advisory committee's meeting on 3 October 2023.
Application Form A for Conditions Group 1 – Inborn Errors of Metabolism
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism — DHPR, hyperphenylalaninemia and PKU conditions only. For other conditions, use Application Form B.
Application Form C – Change of details – Inborn Errors of Metabolism
Individuals registered with the Inborn Errors of Metabolism program can use this form to change their personal information.
Application Form B for Conditions other than Group 1 – Inborn Errors of Metabolism
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism (other than DHPR, hyperphenylalaninemia and PKU).
Application to register as an Approved Metabolic Specialist – Inborn Errors of Metabolism
Specialist doctors can use this form to apply for registration as an approved metabolic specialist under the Inborn Errors of Metabolism (IEM) program.
National Strategy for Health Practitioner Pain Management Education
The National Pain Management Health Practitioner Education Strategy was launched on 6 October 2023. The strategy was developed by the Faculty of Pain Medicine (FPM), Australian and New Zealand College of Anaesthetists (ANZCA) with funding from the Australian Government.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 20 October 2023
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 16th meeting on 20 October 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 23 August 2023
This communique provides a summary of the advisory committee's meeting on 23 August 2023.
National Site of Recognition Steering Committee communique – 10 July 2023
Details of the fifth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 10 July 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 21 July 2023
This communique provides a summary of the advisory committee's meeting on 21 July 2023.
Chronic health plans – Easy Read
This fact sheet tells you about health care plans for chronic health problems. Chronic means something lasts a long time. Chronic health problems last a long time. You can download the fact sheet in PDF to read online or print.
Referral form for chronic disease allied health services under Medicare
GPs can use this referral form to refer a patient with a chronic medical condition and complex care needs for Medicare rebateable allied health services under the Chronic Disease Management (CDM) Medicare items.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 4 July 2023
This communique provides a summary of the advisory committee's meeting on 4 July 2023.
Public consultation on the expansion of newborn bloodspot screening
This report gives an overview of the public consultation process that we undertook for the expansion of newborn bloodspot screening programs.
Newborn bloodspot screening – Public consultation infographic
This publication outlines the key findings from our public consultation on the expansion of newborn bloodspot screening programs.
Date last updated: